MedTrace Logo

Registry on Hypomethylating Agents in Myeloid Neoplasms

NCT01595295 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2024-03-25

No results posted yet for this study

Summary

This registry is set up to collect real-world experience in the management of patients with myeloid neoplasms, in particularly in patients with MDS, CMML or AML, treated with hypomethylating agents in Austria and potentially other participating countries. This registry will collect data in a retrospective as well as in a prospective manner at various sites. The aim is to gain valuable insights on both efficacy and toxicity of these drugs in a routine clinical setting in patients with various comorbidities.

Conditions

Interventions

OTHER

non interventional

Sponsors & Collaborators

  • Arbeitsgemeinschaft medikamentoese Tumortherapie

    lead OTHER

Principal Investigators

  • Richard Greil, MD · Universitätsklinik für Innere Medizin III der PMU Salzburg

  • Lisa Pleyer, MD · Universitätsklinik für Innere Medizin III der PMU Salzburg

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-09
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Austria
  • Croatia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01595295 on ClinicalTrials.gov